BioSpace News Archive

Drug Development

Editas Awaits Data to Determine the Future of Ophthalmic Gene Therapy, EDIT-101

The future of Editas Medicine’s EDIT-101 will be determined later in November after a data readout is available. The data could inform the company whether there is a potential commercial path forward.

November 2, 2022
·
3 min read
·
Alex Keown
Drug Development

uniQure’s High Dose Huntington’s Trial Back on Track Following DSMB Recommendation

A Data Safety Monitoring Board overseeing the Phase Ib/II trial assessing UniQure’s gene therapy for Huntington’s disease recommended that enrollment in the higher-dose cohort could resume.

November 2, 2022
·
3 min read
·
Heather McKenzie
Business

Surface Oncology Pauses CD39 Program, Slashes Workforce by 20%

Surface Oncology announced it is pausing the development of its CD39-targeted antibody SRF617 and cutting around 20% of its workforce to focus on its lead anti-IL-27 program SRF388.

November 2, 2022
·
2 min read
·
Tristan Manalac
Business

CSL Seqirus and Arcturus Ink $4.3 Billion mRNA Vaccine Deal

San Diego-based Arcturus Therapeutics signed a strategic collaboration and licensing deal with CSL Seqirus to help develop and commercialize vaccines.

November 2, 2022
·
2 min read
·
Mark Terry
Policy

GSK RSV Vaccine Candidate Snags Priority Review Designation

GSK scored a pivotal Priority Review from the FDA for its RSV vaccine candidate for older adults, which will expedite regulatory evaluation of its clinical data.

November 2, 2022
·
2 min read
·
Alex Keown
Biotech Bay

Genetown and Biotech Bay Reel in Series A Funds in 2022

After reaching a record high in 2021, venture capital dollars have tailed off in the biopharma industry in 2022. That said, a few biopharma hotbeds have still seen sizeable launch rounds.

November 2, 2022
·
5 min read
·
Heather McKenzie
Business

J.P. Morgan Launches Life Sciences Fund to Support Early-Stage Biotech

J.P. Morgan launched its new life science-focused private equity team, Life Sciences Private Capital, to support early- and growth stage biotech companies.

November 2, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Exelixis Drops $100M on Two Collaborations to Expand Cancer Pipeline

Flush with cash from the growing success of its chemotherapy drug, Exelixis dropped $100M on two collaboration deals this week to invest in promising early clinical assets.

November 2, 2022
·
3 min read
·
Kate Goodwin
Lusaris Launches with $60M to Advance Psychedelic-Based Depression Therapeutic

Lusaris Therapeutics launched with a $60 million Series A financing focus on advancing LSR-1019, a sublingual formulation of 5-MeO-DMT in development for TRD.

November 2, 2022
·
2 min read
·
Mark Terry
Career Advice

Why Q4 May Be the Best Time to Apply to Jobs in the Life Sciences

Q1 is the time when many employers are actively recruiting new talent. Because it takes an average of 60 days to fill a job opening, Q4 might be the best time to apply for jobs in the life sciences.

November 2, 2022
·
3 min read
·
Franklin Carpenter